PA Start Date Therapeutic Class P&T Review Date 7/1/13 TOP$ (Single Drug Reviews) include:

Similar documents
PA Start Date Therapeutic Class P&T Review Date 1/1/17 TOP$ (New Classes) include: Ophthalmics, Anti-Inflammatory/Immunomodulator

PDL Implementation Date 1/1/18 TOP$ (New Classes) include: Epinephrine, Self-Injecting

Texas Vendor Drug Program. Formulary Drug Index File Layout. Layout effective: Jul. 2, 2018 Document update: Oct. 1, 2018

Texas Vendor Drug Program. Formulary Delimited File Layout. April 26, 2017

Relative Cost/Month. Less than $10. Loratadine Liquid* $10-$15 Cetirizine liquid 1mg/mL*

STEP THERAPY ALGORITHMS PUP Select Formulary

Step Therapy Criteria

MEDICAL ASSISTANCE BULLETIN

ADHD STIMULANTS-S(SHC)

Step Therapy Criteria

Commissioner for the Department for Medicaid Services Selections for Preferred Products

Secretary for Health and Family Services Selections for Preferred Products

ADHD STIMULANTS - SCORE

ADHD STIMULANTS - SCORE

CONTENTS SECTION 1 SECTION

Beneficiary Advisory Panel Handout Uniform Formulary Decisions 23 June 2011

FirstCarolinaCare Insurance Company Step Therapy Requirements

New Product to Market: Trelegy Ellipta Magellan Health, Inc. All rights reserved.

IHCP bulletin INDIANA HEALTH COVERAGE PROGRAMS BT NOVEMBER 30, 2010

SmithRx Standard Formulary Step Therapy List

Medication and Dose 10/04/ /05/2016 Total % Change Since 10/2012 ABILIFY 10 MG TABLET $18.76 $ %

MEDICAL ASSISTANCE BULLETIN

ALOGLIPTIN STEP. Step Therapy Requirements Effective April 1, 2018

ALOGLIPTIN STEP. Step Therapy Requirements Effective June 1, 2018

ANTIDEPRESSANTS. Details. Step Therapy 2018 Last Updated: 8/21/2018

Essentials for Medication Safety

North Dakota Medicaid Therapeutic Duplication Edits

Michigan Department of Health and Human Services Pharmacy and Therapeutics Committee

ANGIOTENSIN RECEPTOR BLOCKERS

IHCP bulletin INDIANA HEALTH COVERAGE PROGRAMS BT MAY 29, 2012

South Carolina Department of Health and Human Services Post Office Box 8206 Columbia, South Carolina

Kentucky Department for Medicaid Services. Drug Review Options

Drug Classification and Pharmacologic Actions

Kentucky Department for Medicaid Services Pharmacy and Therapeutics Advisory Committee Recommendations

Drugs Categories. 4. Which suffix do erectile dysfunction generic drug names often end with?

MEDICAL ASSISTANCE BULLETIN

Alameda Alliance for Health Pharmacy & Therapeutics (P&T) Committee Decisions

Drug Classifications

South Carolina Department of Health and Human Services Post Office Box 8206 Columbia, South Carolina

Management. Quantity. What Is Quantity Management? What Happens at the Pharmacy? Which Medications Are Included? January 2016

ANTIDEPRESSANTS. Details. Step Therapy 2017 Last Updated: 5/23/2017

Michigan Pharmacy and Therapeutics Committee

Drug Classifications

Alabama Medicaid Preferred Drug and Prior Authorization Program

Quarterly pharmacy formulary change notice

Quarterly pharmacy formulary change notice

DOD PHARMACY AND THERAPEUTICS COMMITTEE RECOMMENDATIONS INFORMATION FOR THE UNIFORM FORMULARY BENEFICIARY ADVISORY PANEL

Appropriate Use & Safety Edits

Quarterly pharmacy formulary change notice

2015 Step Therapy Prior Authorization Medical Necessity Guidelines

ALOGLIPTIN STEP. Details. Step Therapy Requirements Effective November 1, 2017

Pharmacy Updates Summary

South Carolina Department of Health and Human Services Post Office Box 8206 Columbia, South Carolina

ANGIOTENSIN RECEPTOR BLOCKERS STEP THERAPY

Quantity Management. October 2017

Step Therapy Requirements. Effective: 03/01/2015

Step Therapy Requirements. Effective: 12/01/2016

Quarterly pharmacy formulary change notice

STATE OF TENNESSEE DEPARTMENT OF FINANCE AND ADMINISTRATION DIVISION OF HEALTH CARE FINANCE AND ADMINISTRATION BUREAU OF TENNCARE

JANUVIA 50 MG TABLET BYDUREON 2 MG/0.65 ML JARDIANCE 10 MG TABLET SUBCUTANEOUS PEN INJECTOR JARDIANCE 25 MG TABLET BYDUREON BCISE 2 MG/0.

Management. Quantity. What Is Quantity Management? What Happens at the Pharmacy? Which Medications Are Included? January 2017

5-ASA. Products Affected Dipentum 250 mg capsule. Details. Lialda 1.2 gram tablet,delayed release

CRITERIA Trial of two generic formulary products from the following: atomoxetine or ADHD stimulant medication.

ALLERGIC CONJUNCTIVITIS AGENTS

ANTIEMETICS STEP. Step Therapy Requirements Effective April 1, 2019

Oregon Health Plan prescription benefit updates

Connecticut Medicaid P&T Meeting Minutes June 5, 2008

Quarterly pharmacy formulary change notice

Quarterly pharmacy formulary change notice

Connecticut Medicaid P&T Meeting Minutes March 20, 2008

Quarterly pharmacy formulary change notice

Step Therapy Criteria 2019

Kentucky Department for Medicaid Services Drug Review and Options for Consideration

CONTRAINDICATIONS TABLE

5-ASA. Products Affected DIPENTUM 250 MG CAPSULE LIALDA 1.2 GRAM TABLET,DELAYED RELEASE. Details

5-ASA. Products Affected. Details. Dipentum 250 mg capsule. Lialda 1.2 gram tablet,delayed release

Kentucky Department for Medicaid Services. Drug Review Options

Secretary for Health and Family Services Selections for Preferred Products

Nclex para la Enfermera Hispana

RxBlue 2010 ST Criteria

Michigan Pharmacy and Therapeutics Committee September 11, Minutes

Quarterly pharmacy formulary change notice

ALBUTEROL - SCORE. Products Affected. Details. Step Therapy Criteria Health Choice Generations 1 Tier Gold Effective Date: 11/01/2018.

ARBS MEDICATION(S) SUBJECT TO STEP THERAPY DIOVAN HCT MG TAB, DIOVAN HCT MG TABLET

ALBUTEROL - SCORE. Products Affected. Details. Step Therapy Criteria Optima Tier Gold Formulary Date Effective: November 1, 2018.

Drug / Pregnancy Conflicts Excessive Daily Doses Ingredient Duplication Insufficient Daily Doses

U T I L I Z A T I O N E D I T S

STEP THERAPY CRITERIA

2015 Essential PDL to Advantage PDL Comparison

MEDICAID BULLETIN. Providers Indicated

Quarterly pharmacy formulary change notice

Connecticut Medicaid P&T Meeting Minutes June 4, 2009

Quarterly pharmacy formulary change notice

Transcription:

Maryland Department of Health and Mental Hygiene PDL Prior Authorization Implementation Schedule PA Start Therapeutic Class P&T Review 7/1/13 5/2/13 Antidepressants, Other (ForfivoXL) COPD Agents (Tudorza Pressair) Cytokine and CAM Antagonists (Xeljanz) Neuropathic Pain (Lyrica Solution) Ophthalmics, Anti-Inflammatories (Ilevro, Lotemax Gel) Stimulants and Related Agents (Quillivant, XR, Kapvay ER Dose Pack) 1/1/13 TOP$ (New Classes) include: 11/8/12 Neuropathic Pain Analgesics, Narcotics Short Acting (Primlev, Subsys) Antiparasitics, Topical (Sklice) Erythropoiesis Stimulating Proteins (Omontys) Hypoglycemics, Incretin Mimetics/Enhancers (Janumet XR) 7/1/12 Anticonvulsants (Onfi) NSAIDs (Duexis) 5/10/12 1/1/12 TOP$ (New Classes) include: Antihypertensives, Sympatholytics Ophthalmic Antibiotic/Steroid Combinations Androgenic Agents (Axiron) Angiotensin Modulators (Edarbi) Antibiotics, GI (Dificid) Anticoagulants (Xarelto) Hepatitis C Agents (Ribapak, Incivek, Victrelis) Hypoglycemics, Incretin Mimetics/ Enhancers (Tradjenta) 7/1/11 Antidepressants, Other (Oleptro ER) Antihistamines, Minimally Sedating (Claritin Liqui-Gels) Antipsychotics (Latuda) Glucocorticoids, Inhaled (Dulera) Ophthalmics, Antibiotics (Moxeza and Zymaxid) Ophthalmics for Allergic Conjunctivitis (Lastacaft) Ophthalmics, Anti-Inflammatories (Bromday) 11/3/11 5/24/11

PA Start Therapeutic Class P&T Review Sedative Hypnotics (Silenor and Zolpimist) Stimulants and Related Agents (Kapvay) 10/1/10 TOP$ (New Classes) include: Antibiotics, Inhaled Bile Salts Acne Agents, Topical (SE BPO) Analgesics, Narcotics Long (Exalgo) Analgesics, Narcotics Short (Rybix ODT) Immunosuppressives, Oral (Zortress) MS Agents (Ampyra) Proton Pump Inhibitors (Zegerid OTC) 8/19/10 4/1/10 TOP$ (New Classes) include: Colony Stimulating Factors Fibromyalgia Agents Immunosuppressives, Oral Antifungals, Oral (Terbinex) Anti-Hyperuricemics (Colcrys) Antiparasitics, Topical (Ulesfia) Antipsychotics (Saphris; Invega Sustenna) Cytokine and CAM Antagonists (Simponi; Stelara) Hypoglycemics, Incretins (Onglyza) NSAIDs (Zipsor) Ophthalmics for Allergic Conjunctivitis (Bepreve) Ophthalmics, Anti-Inflammatories (Acuvail; Ozurdex) Ophthalmics, Antibiotics (Besivance) Pancreatic Enzymes (Zenpep) Platelet Aggregation Inhibitors (Effient) Stimulants and Related Agents (Intuniv; Nuvigil) 10/1/09 TOP$ (New Classes) include: Antihyperuricemics Antifungals, Topical Tetracyclines Analgesics, Short-Acting Narcotics (Dilaudid Liquid) Anticonvulsants (Banzel; Vimpat) Bladder Relaxants (Toviaz) BPH Agents (Rapaflo) Hypoglycemics, Meglitinides (Prandimet) 3/2/10 8/20/09

PA Start Therapeutic Class P&T Review Lipotropics, Other (Trilipix) Phosphate Binders (Eliphos) Proton Pump Inhibitors (Kapidex; Prilosec Suspension) Ulcerative Colitis Agents (Apriso;sfRowasa) 4/1/09 TOP$ (New Class) includes: PAH Agents, Oral Antidepressants, Other (Venlafaxine ER) Antiemetics (Sancuso) Antifungals, Topical (Xolegel Corepak; Xolegel Duo) Anti-Parkinson s Agents (Requip XL) Glucocorticoids, Inhaled (Alvesco) Intranasal Rhinitis Agents (Patanase) 10/1/08 TOP$ (New Classes) include: Analgesics/Anesthetics, Topical Antibiotics, Vaginal Antiparasitics, Topical Pancreatic Enzymes Acne Agents, Topical (Atralin) Antihistamines, Minimally Sedating (Allegra ODT; cetirizine; cetirizine D; cetirizine syrup) Beta Blockers (Bystolic) Lipotropics, Other (Fenoglide) Lipotropics, Statins (Simcor) Phosphate Binders (Renvela) 4/1/08 TOP$ (New Classes) include: Antibiotics, GI Impetigo Agents, Topical Skeletal Muscle Relaxants Alzheimer s Agents (Exelon Patch) Antifungals, Topical (Extina) Anti-Parkinson s Agents (Neupro Patch) Bronchodilators, Long-Acting Beta Agonists (Brovana and Perforomist) Glucocorticoids, Inhaled (Symbicort) Intranasal Rhinitis Agents (Veramyst) Leukotriene Modifiers (Zyflo CR) Ophthalmics, Fluoroquinolones and Macrolides (AzaSite) 2/5/09 8/21/08 2/14/08

PA Start Therapeutic Class P&T Review Stimulants and Related Agents (Vyvanse) 10/2/07 TOP$ (New Classes) include: Hepatitis B Agents Ophthalmics, NSAIDs Atypical Antipsychotics (to be implemented 1/1/08) Acne Agents, Topical (Ziana) Analgesics, Short-Acting Narcotics (Fentora) Antihistamines, Minimally Sedating (Allegra Syrup and Claritin Chewable OTC) Beta Blockers (Coreg CR) Growth Hormones (Omnitrope) Proton Pump Inhibitors (Nexium Suspension) Ulcerative Colitis Agents (Lialda) 4/3/07 Antifungals, Oral (Noxafil) Antifungals, Topical (Xolegel) Anti-Parkinson s Agents (Azilect and Zelapar) Hypoglycemics, Insulins and Related Agents (Exubera) Stimulants and Related Agents (Daytrana) 10/3/06 TOP$ (New Class) includes: Androgenic Agents Analgesic Narcotics (Ultram ER) Hypoglycemics, TZDs (Avandaryl) Proton Pump Inhibitors (Zegerid- Oral Solid Forms) 4/4/06 TOP$ (New Classes) include: Acne Agents, Topical Anticonvulsants Bone Resorption Suppressants (Actonel with Calcium; Fortical) Fluoroquinolones, Oral (Proquin XR) Glucocorticoids, Inhaled (Asmanex) 10/6/05 TOP$ (New Classes) include: Alzheimer s Agents Anti-Parkinson s Agents 8/9/07 2/8/07 8/17/06 2/9/06 8/18/05

PA Start Therapeutic Class P&T Review Atopic Dermatitis Hypoglycemics, Metformins Ophthalmics, Glaucoma Agents Platelet Aggregation Inhibitors Analgesics, Narcotics (Combunox) Sedative Hypnotics (Lunesta) 7/6/05 TOP$ (New Classes) include: 3/8/05 Anticoagulants, Injectable Growth Hormones (CLINICAL PA also) Sedative Hypnotics Ulcerative Colitis Agents 1/23/05 Bronchodilators, Anticholinergics 12/2/04 11/3/04 Antidepressants (SSRIs)- Symbyax ONLY 9/23/04 Antimigraine Triptans- Relpax ONLY 7/21/04 Antidepressants, SSRIs Pexeva; Antivirals 6/10/04 Valtrex; Beta Blockers Innopran XL; Disease Modifying Antirheumatic Drugs; Erectile Dysfunction Agents; Erythropoietins; Hepatitis C Agents; Multiple Sclerosis Agents; NSAIDs Prevacid Naprapac; Ophthalmics, Allergic Conjunctivitis -- Elestat 5/19/04 Antihistamines, Minimally Sedating; Phosphate 3/18/04 Binders 5/12/04 Antidepressants, Other; Beta Blockers Inderal LA 3/18/04 and Innopran XL; Bladder Relaxants; Lipotropics, Statins Crestor; Ophthalmics, Allergic Conjunctivitis; Ophthalmics, Antibiotics; Otics, Antibiotics 2/4/04 Antidepressants, SSRIs; Antiemetics; Beta-Agonist 12/11/04 Bronchodilators; Claudication Agents; Hypoglycemics, Meglitinides; Stimulants and Related Agents 1/21/04 Antifungals, Oral; Cephalosporins and Related 10/23/03 Antibiotics; Antifungals, Topical; Hypoglycemics, Insulins 1/7/04 Antimigraine Agents, Triptans; Analgesics, Narcotic; 10/23/03 Bone Resorption Suppression and Related Agents; Estrogen Agents, Combination; Estrogen Agents, Oral and Transdermal 12/17/03 Macrolides; Antivirals; Hypoglycemics, 10/23/03 Thiazolidinediones; Fluoroquinolones 12/03/03 ACE Inhibitors; Calcium Channel Blocking Agents; 9/10/03 Lipotropics, Statins 11/19/03 Angiotensin Receptor Blockers; Nasal 9/10/03 Corticosteroids; NSAIDs/COX II Inhibitors 11/05/03 ACE Inhibitor/Calcium Channel Blocker Combination; Benign Prostatic Hyperplasia; Beta Blockers; Inhaled Corticosteroids; Leukotriene Receptor Antagonists; Lipotropics, Other; Proton Pump Inhibitors 9/10/03